Insulin-Like Growth Factor Receptor (IGF1R and IGf2R)

Product #

Description

Biochem/physiol Actions

Add to Cart

BM0028 BMS-536924 ≥98% (HPLC) BMS-536924 is a potent, orally active, ATP-competitive insulin-like growth gactor-1 receptor (IGF1R) inhibitor that shows anticancer activities in preclinical models.
BM0003 BMS-754807 ≥98% (HPLC) BMS-754807 is an orally available and potent dual insulin-like growth factor factor-1 receptor (IGF-1R)/ insulin receptor (InsR) tyrosine kinase inhibitor that synergistically enhances antiproliferative effects of 4-hydroxytamoxifen, letrozole, and fulvestrant in MCF-7/AC-1 cells.
SML0995 GSK1838705A ≥98% (HPLC) GSK1838705A is a cell penetrant anti-tumor agent that potently inhibits the insulin-like growth factor-I receptors (IGF-IR), insulin receptors (IR) and anaplastic lymphoma kinase (ALK). GSK1838705A potently inhibits cell proliferation of multiple solid and hematologic cancers and retards the growth of human tumor xenografts. GSK1838705A does not significantly affect other kinases. GSK1838705A has minimal effects on glucose homeostasis in mice.
T9576 Picropodophyllotoxin ≥96% (HPLC), powder Picropodophyllotoxin (PPP), an epimer of podophyllotoxin (PPT), has been reported to target insulin-like growth factor-I receptor (IGF-IR) and mediate anticancer functions. However, a study in 2007, has reported that PPP can induce G2-M cell cycle arrest even in IGF-IR deficient cells. Hence, the role of PPP in IGF-IR-mediated anticancer functions is debatable.
Picropodophyllotoxin is an insulin-like growth factor-I (IGF-I) receptor kinase inhibitor.
P0113 PQ401 ≥98% (HPLC), powder PQ401 is an insulin growth factor-1 receptor (IGF-1R) inhibitor.
T7697 I-OMe-Tyrphostin AG 538 solid Insulin growth factor 1 (IGF-1) receptor protein tyrosine kinase inhibitor.